Accurately identify those at risk, and proactively devise a treatment plan

Here, the author answers questions from OM about a technology, based on firsthand experience with it.

Please describe the Aladdin-M.

The Aladdin-M, from Topcon Healthcare, combines corneal topography, pupillometry and optical biometry. The instrument utilizes optical low coherence interferometry to acquire axial length, which aids clinicians in the management of the myopic patient.

What patients will benefit from the use of the device?

The corneal topographical information and white-to-white measurements, in combination with analyzing corneal wavefront aberrations, pupillometry and refractive error make this instrument a go-to for assessing all patients. But, again, the ability to accurately track axial length, according to a study in the British Journal of Ophthalmology, along with refractive error is essential for the improved management of the young myope.

How do you bill for Aladdin-M?

The Aladdin-M is billable to insurance by utilizing topography CPT code 92025 (computerized corneal topography, unilateral or bilateral, with interpretation and report) with an appropriate corneal or monocular diplopia diagnostic code. There also is an optical coherence biometry code 92136 (ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation) that is traditionally used prior to cataract extraction.

However, these codes are often not a covered expense with certain carriers (refer to each carrier for specifics). In such instances, when utilizing the Aladdin-M to manage contact lens or cornea cases, the practice may consider incorporating this technology fee into their out-of-pocket global service fee.

What results can an O.D. expect from using this technology?

Based on my experience, O.D.s can expect accurate, efficient measurements. The rapid capture time and ease of use make it ideal to quickly train technicians and enhance patient flow. The reports that track changes in refraction and axial elongation aid in following myopic progression to allow the clinician to appropriately monitor patients and alter treatment plans for better outcomes.

For what percentage of patients have you utilized Aladdin-M?

We’ve found that, by using the technology in our pediatric population, about 23% of our patients are at risk for myopia. That number is growing as our practice continues to educate the community.

How do you educate patients on the Aladdin-M technology?

As soon as we determine a child is in need of myopia treatment, we schedule a separate visit to fully educate both the parents and the child on how we will be managing the condition. We have a global myopia management fee that includes the testing corresponding to the patient’s treatment plan. We let parents know we will be utilizing the latest technology to track the amount of myopia, along with the physical length of the eye to help improve outcomes by appropriately adjusting treatment. We take Aladdin-M measurements bi-annually and as needed. OM

DR. LOWE is is director/owner of Professional Eye Care Center, a full-scope primary care practice. She is the Medical Director of Vision Source Chicagoland and serves on the AOA Contact Lens and Cornea Section. Dr. Lowe is a consultant for Alcon, Essilor, Maculogix, Topcon, Visible Genomics and ZeaVision.